BACKGROUND: Follicular lymphoma (FL) occurs predominantly at advanced age, with an annual incidence of 3-5 cases per 100 000 inhabitants in Western countries. The clinical course is heterogeneous. METHODS: For this new guideline, systematic literature searches were conducted in medical databases (MEDLINE, PubMed Central) (up to November 2017) and in the Guidelines International Network (G-I-N), and recent publications were added. RESULTS: The results of 21 systematic reviews with meta-analyses, 75 randomized controlled trials, and 58 prospective and retrospective studies were evaluated. Lymph-node biopsy is necessary for initial diagnosis of FL. CT scanning of the neck, thorax, and abdomen should be performed to assess how far the disease has spread, together with bone marrow biopsy and, if required, PET/CT. In early FL (stages I and II; 10-15 %), potentially curative radiotherapy combined with an anti-CD 20 antibody is recommended. In advanced disease (stages III and IV), watchful waiting is indicated for patients who have no clinical symptoms and a low tumor burden. Patients with clinical symptoms and/or high tumor burden should receive chemotherapy in combination with an anti-CD 20 antibody, followed by 2 years' maintenance treatment with an anti-CD 20 antibody. CONCLUSION: Given the good long-term prognosis of FL, the treatment must be chosen with care and thorough follow-up is necessary to ensure detection of late sequelae such as second malignancies or organ damage.
BACKGROUND: Follicular lymphoma (FL) occurs predominantly at advanced age, with an annual incidence of 3-5 cases per 100 000 inhabitants in Western countries. The clinical course is heterogeneous. METHODS: For this new guideline, systematic literature searches were conducted in medical databases (MEDLINE, PubMed Central) (up to November 2017) and in the Guidelines International Network (G-I-N), and recent publications were added. RESULTS: The results of 21 systematic reviews with meta-analyses, 75 randomized controlled trials, and 58 prospective and retrospective studies were evaluated. Lymph-node biopsy is necessary for initial diagnosis of FL. CT scanning of the neck, thorax, and abdomen should be performed to assess how far the disease has spread, together with bone marrow biopsy and, if required, PET/CT. In early FL (stages I and II; 10-15 %), potentially curative radiotherapy combined with an anti-CD 20 antibody is recommended. In advanced disease (stages III and IV), watchful waiting is indicated for patients who have no clinical symptoms and a low tumor burden. Patients with clinical symptoms and/or high tumor burden should receive chemotherapy in combination with an anti-CD 20 antibody, followed by 2 years' maintenance treatment with an anti-CD 20 antibody. CONCLUSION: Given the good long-term prognosis of FL, the treatment must be chosen with care and thorough follow-up is necessary to ensure detection of late sequelae such as second malignancies or organ damage.
Authors: Georg Lenz; Martin Dreyling; Eva Schiegnitz; Torsten Haferlach; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2004-12-15 Impact factor: 44.544
Authors: Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly Journal: Lancet Date: 2010-12-20 Impact factor: 79.321
Authors: Ur Metser; Jill Dudebout; Tara Baetz; David C Hodgson; Deanna L Langer; Pamela MacCrostie; Victor Mak; Noam Tau Journal: Cancer Date: 2017-03-13 Impact factor: 6.860
Authors: Rudolf Weide; Stefan Feiten; Vera Friesenhahn; Jochen Heymanns; Kristina Kleboth; Jörg Thomalla; Christoph van Roye; Hubert Köppler Journal: Leuk Lymphoma Date: 2012-12-05
Authors: Andrew Wirth; Marcus Foo; John F Seymour; Michael P Macmanus; Rodney J Hicks Journal: Int J Radiat Oncol Biol Phys Date: 2008-03-04 Impact factor: 7.038
Authors: S Wöhrer; U Jaeger; K Kletter; A Becherer; A Hauswirth; K Turetschek; M Raderer; M Hoffmann Journal: Ann Oncol Date: 2006-02-23 Impact factor: 32.976
Authors: Carla Casulo; Jonathan W Friedberg; Kwang W Ahn; Christopher Flowers; Alyssa DiGilio; Sonali M Smith; Sairah Ahmed; David Inwards; Mahmoud Aljurf; Andy I Chen; Hannah Choe; Jonathon Cohen; Edward Copelan; Umar Farooq; Timothy S Fenske; Cesar Freytes; Sameh Gaballa; Siddhartha Ganguly; Yogesh Jethava; Rammurti T Kamble; Vaishalee P Kenkre; Hillard Lazarus; Aleksandr Lazaryan; Richard F Olsson; Andrew R Rezvani; David Rizzieri; Sachiko Seo; Gunjan L Shah; Nina Shah; Melham Solh; Anna Sureda; Basem William; Aaron Cumpston; Andrew D Zelenetz; Brian K Link; Mehdi Hamadani Journal: Biol Blood Marrow Transplant Date: 2017-12-11 Impact factor: 5.742
Authors: Emmanuel Bachy; John F Seymour; Pierre Feugier; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; John V Catalano; Pauline Brice; François Lemonnier; Alejandro Martin; Olivier Casasnovas; Lars M Pedersen; Véronique Dorvaux; David Simpson; Sirpa Leppa; Jean Gabarre; Maria G da Silva; Sylvie Glaisner; Loic Ysebaert; Anne Vekhoff; Tanin Intragumtornchai; Steven Le Gouill; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Jonathan Farhi; Harald Zeuner; Hervé Tilly; Gilles Salles Journal: J Clin Oncol Date: 2019-07-24 Impact factor: 44.544